Etrasimod - Latest news on Velsipity and domestic and overseas launch trends

Etrasimod tablets (Etrasimod), as a new type of immunomodulatory drug, are mainly used to treat moderately to severe active ulcerative colitis and related autoimmune diseases. In 2023October , FDA officially approved its marketing, marking the recognition of the clinical application of Itramod on a global scale. The drug exerts an immunomodulatory effect by regulating the activity of the S1P receptor subtype, thereby reducing the intestinal inflammatory response and providing a new treatment option for patients.

in the country, Itramod tablets have not yet received marketing approval and are therefore not yet included in medical insurance. If patients have relevant medication needs, they can currently only rely on overseas formal channels to purchase original drugs. This also means that domestic patients have certain difficulties in obtaining drugs, and they need to make international purchases under the guidance of doctors, while paying attention to drug transportation and quality and safety issues.

In overseas markets, the originator drugs of Itramod tablets mainly include the European version and the American version. The price of each box of the European version may range from RMB 10,000 to RMB 30,000, while the price of the American version is usually slightly higher. Since the drug is a newly launched product and there are no generic drugs on the market yet, the price remains at a high level, which also reflects its R&D investment and clinical value.

Currently, there are no generic versions of Itrimod tablets available in China, which means that patients can only rely on the original drug to meet their treatment needs in the short term. With the advancement of clinical research and international marketing, generic drugs may enter the market in the future, thereby reducing medication costs and improving patient accessibility. Prior to this, patients should evaluate the risks and benefits under the guidance of a professional doctor and reasonably arrange medication and treatment plans.

Reference materials:https://pubmed.ncbi.nlm.nih.gov/38388871/